Combination of Nivolumab and Ipilimumab in Breast, Ovarian and Gastric Cancer Patients
Stopped early · Phase 2
Conditions studied: Breast Cancer Female, Ovarian Cancer, Gastric Cancer
In brief
Safety and tolerability of combination of Nivolumab and Ipilimumab will be studied in patients with 3 different types of cancers in 3 parts of the study, as shown below: Part 1 - Neoadjuvant Therapy of Breast Cancer; Part 2 - Therapy of Ovarian Cancer; and Part 3 - Therapy of Gastric Cancer.
Key facts
- Study ID
- NCT03342417
- Run by
- ExcellaBio LLC
- People needed
- 5
- Starts
- 2018-02-14
- Expected to finish
- 2019-05-29
- Last updated by the study team
- 2021-11-09
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Hoffman Oncology — The Bronx, New York, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.